Artículo
Whole transcription profile of responders to anti-tnf drugs in pediatric inflammatory bowel disease
Autor/es | Salvador-Martín, Sara
Kaczmarczyk, Bartosz Álvarez, Rebeca Navas-López, Víctor Manuel Gallego-Fernández, Carmen Moreno-Álvarez, Ana Merino Bohórquez, Vicente López-Fernández, Luís A. |
Departamento | Universidad de Sevilla. Departamento de Farmacología, Pediatría y Radiología |
Fecha de publicación | 2021-01-08 |
Fecha de depósito | 2021-02-10 |
Publicado en |
|
Resumen | Background: Up to 30% of patients with pediatric inflammatory bowel disease (IBD) do not respond to anti-Tumor Necrosis Factor (anti-TNF) therapy. The aim of this study was to identify pharmacogenomic markers that predict ... Background: Up to 30% of patients with pediatric inflammatory bowel disease (IBD) do not respond to anti-Tumor Necrosis Factor (anti-TNF) therapy. The aim of this study was to identify pharmacogenomic markers that predict early response to anti-TNF drugs in pediatric patients with IBD. Methods: An observational, longitudinal, prospective cohort study was conducted. The study population comprised 38 patients with IBD aged < 18 years who started treatment with infliximab or adalimumab (29 responders and nine non-responders). Whole gene expression profiles from total RNA isolated from whole blood samples of six responders and six non-responders taken before administration of the biologic and after two weeks of therapy were analyzed using next-generation RNA sequencing. The expression of six selected genes was measured for purposes of validation in all of the 38 patients recruited using qPCR. Results: Genes were differentially expressed in non-responders and responders (32 before initiation of treatment and 44 after two weeks, Log2FC (Fold change) >0.6 or <−0.6 and p value < 0.05). After validation, FCGR1A, FCGR1B, and GBP1 were overexpressed in non-responders two weeks after initiation of anti-TNF treatment (Log2FC 1.05, 1.21, and 1.08, respectively, p value < 0.05). Conclusion: Expression of the FCGR1A, FCGR1B, and GBP1 genes is a pharmacogenomic biomarker of early response to anti-TNF agents in pediatric IBD |
Identificador del proyecto | PI16 / 00559 y PI19 / 00792
PEJ16 / MED / AI-1260 PRE2018-2 |
Cita | Salvador-Martín, S., Kaczmarczyk, B., Álvarez, R., Navas-López, V.M., Gallego-Fernández, C., Moreno-Álvarez, A.,...,Merino-Bohórquez, V. (2021). Whole transcription profile of responders to anti-tnf drugs in pediatric inflammatory bowel disease. Pharmaceutics, 13 (1), 1-17. |
Ficheros | Tamaño | Formato | Ver | Descripción |
---|---|---|---|---|
Whole transcription profile of ... | 4.745Mb | [PDF] | Ver/ | |